January 25th 2023
If approved on its March PDUFA date, rezafungin could be the first new Candida treatment option in over a decade.
January 18th 2023
Sepsis is the number 1 cause of death in hospitals. The FDA approval of IntelliSep, the first sepsis diagnostic tool, could change this.
January 16th 2023
Fecal microbiota transplantation (FMT) is known to be an effective treatment for recurrent Clostridioides difficile infection. New research reveals why.
December 5th 2022
Enteric pathogens increase C difficile virulence by providing amino acids that shape the metabolic environment in the gut.
November 25th 2022
November is C difficile Awareness Month. We're recapping the most significant potential therapies and remaining challenges from the past month.
Containing an Outbreak of Carbapenem-Resistant Acinetobacter baumannii in a COVID-19 Isolation Unit
COVID-19 isolation wards should employ additional contact precautions and environmental cleaning alongside regular COVID-19 precautions, such as personal protective equipment, in order to prevent multidrug-resistant infections.
A 4-Year Antimicrobial Stewardship Program Successfully Reduces Antibiotic Resistance
Antimicrobial stewardship works, one IDWeek 2022 study found.
FMT Cost-Effective for 90% of Recurrent C Difficile Infections
Compared to fidaxomicin and vancomycinfecal, microbiota transplant (FMT) was the most cost-effective treatment for first and subsequent recurrent C difficile infection.
Recurrence Escalates Financial Burden of CDI
Frequent recurrence of Clostridioides difficile infection drives up financial burdens of the disease and underscores the need to improve access to treatment, infection prevention, and new therapies.
Hospitalizations and Drug Prescriptions in Patients Pre- and Post-Sepsis
Hospitalization rates increased significantly after sepsis, with 11.9% of survivors rehospitalized for recurrent sepsis, and 56.6% receiving outpatient anti-infective treatment.
Hospitalized C Diff Patients May Pass Infection to Family
People exposed to a family member recently hospitalized with C difficile infection were 73% more likely to contract CDI themselves.
Investigational Microbiome Therapeutic SER-109 Reduces C Difficile Recurrence
SER-109, the investigational oral microbiome therapeutic from Seres, reduced C diff recurrence by 91.3% in at-risk populations.
Pediatric UTI Risk Assessments and Race
Investigators performed a systematic review to assess just how strong the association between race and urinary tract infections (UTIs) in children.
Rifaximin Effective in Majority of Patients Recurrent CDI Who Do Not Respond to Metronidazole
About 65% of patients with metronidazole-resistant recurrent C difficile infection benefitted from taking rifaximin.
Novel Antibiotics for Resistant Pathogens: Results of ATTACK Trial for Sulbactam-Durlobactam
Entasis Therapeutics gave 2 oral presentations at ECCMID today detailing results of their ATTACK trial, investigating the safety and efficacy of sulbactam-durlobactam (SUL-DUR) for multidrug-resistant pathogens.
COVID-19 Pandemic May Have Accelerated Antimicrobial Resistance
During the pandemic, antibiotic-resistant bacterial infections increased in hospitalized patients who tested positive or negative for COVID-19.
Identifying High-Risk Recurrent Clostridioides Difficile Patients for Bezlotoxumab
The greatest risk factors for recurrent Clostridioides difficile infection (CDI) were age of at least 65 years, severe primary CDI, and use of non-CDI antibiotics. Patients with these risk factors should be prioritized for bezlotoxumab therapy.
Initiating Antibiotic for Severe Pneumonia from Gram Staining Could Reduce Broad Spectrum Agents
Selecting initial antibiotic for ventilator-associated pneumonia from Gram staining and resistance records could reduce broad spectrum agents.
Vancomycin Nonsusceptibility Common in CDI Cases
A new report based on samples from Texas and Kenya found significant proportions of samples from patients with CDI had nonsusceptible isolates.
New Visual of C Difficile Armor Explains its Resilience
For the first time, a research team mapped C difficile’s outer “S-layer,” finding the dangerous bacteria’s chainmail-like shell enables it to be highly resistant.
Nursing Homes at Increased Risk of Antibiotic Resistant Infections
To reduce antimicrobial resistant pathogens, nursing homes should carefully monitor their use of hospital-grade antibiotics.
Hospitals That Use More Antibiotics Have More C Difficile Infections
Hospitals with lower c difficile antibiotic usage averaged shorter length-of-stay than hospitals that prescribed more antibiotics.
Adhering to Standard for Sepsis Treatment Did Not Reduce Mortality
Implementation of CMS Severe Sepsis and Septic Shock Management Bundle did not reduce mortality rates in study of 114 hospitals.
Ferring’s Microbiome Health Index Measures Gut Microbiota After Antibiotics
Ferring’s Microbiome Health Index is a diagnostic tool that may help distinguish a healthy gut microbiome from post-antibiotic dysbiosis, and could potentially identify debilitating illnesses such as C difficile infection
COVID-19 Patients Indicated for More Severe C Difficile Outcomes
COVID-19 patients were not at increased risk of Clostridium difficile infection. However, those already infected with C diff were more likely to experience severe outcomes.
Candida auris: Coming Soon to a Facility Near You?
Epidemiologic and clinical lessons for the uninitiated.
5 Strategies for Improving Sepsis Care Management
Hospitalists can be better equipped to identify patients most in need of intervention and standardize sepsis management efforts.
CMS Program Appears to Succeed at Lowering Hospital CDI Rates
Hospital-onset CDI rates dropped by 6% in the first quarter of the program, which launched in 2016.
FDA Approves Maribavir for CMV Infections After Transplant
The federal agency's decision makes this the first CMV treatment for this patient population.
I Kidney Not: Antibiotic Dosing Strategies in Intermittent Hemodialysis
In the latest article from SIDP, here is a look at the use of various intravenous (IV) antimicrobial therapies to address infections in these patients.
Risk Factors Associated with C Diff Infection
Incidences of Clostridioides difficile infection have risen in recent years, and understanding risk factors can help practitioners address associated mortality, morbidity and health care costs.
Bacterial Infections Linked with Unapproved Stem Cell Treatments
Unapproved stem cell treatments derived from umbilical cord blood can pose potential risks to patients without proven benefits, a CDC study shows.
Reducing Peripheral Venous Catheter Infections
Lack of data may mean bloodstream infections caused by PVCs are an overlooked cause of morbidity in hospitalized patients.
What Is the Ideal Duration of Daptomycin and Ceftaroline Combination Therapy for MRSA Bacteremia?
Probiotics Do Not Aid Prevention of Ventilator-Assisted Pneumonia
Investigators found no significant difference among hospitalized patients in the ICU being administered probiotics vs placebo.
2 Clarke Drive Cranbury, NJ 08512